BPX-201 Vaccine for Chemotherapy-Naïve mCRPC
Thomas E. Hutson, DO, PharmD, medical oncologist, Texas Oncology–Baylor Charles A. Sammons Cancer Center, discusses a phase I study of BPX-201 vaccine plus AP1903 for chemotherapy-naïve mCRPC.
Clinical Pearls
Thomas E. Hutson, DO, PharmD, medical oncologist, Texas OncologyBaylor Charles A. Sammons Cancer Center, discusses a phase I study of BPX-201 vaccine plus AP1903 for chemotherapy-naïve metastatic castration-resistant prostate cancer (mCRPC).
- BPX-201 is novel, second-generation, autologous antigen presenting cell-based vaccine.
- In a previous phase I trial, this has proven to be a potent approach to vaccination against prostate cancer.
- There is hope that this approach will lead to both survival benefit and real-time benefit in the form of tumor responses and PSA reductions.
- To date, 6 patients have been enrolled in the trial and no dose-limiting toxicities have been observed.
<<<
Recent Videos
Related Content
ENVISION Trial of UGN-102 Shows Durable Responses in LG-IR-NMIBC
February 3rd 2025Article
Data from the phase 3 ENVISION trial demonstrate the potential of UGN-102 as an effective and durable nonsurgical treatment for patients with low-grade, intermediate-risk non–muscle-invasive bladder cancer.
Read More
